Welcome to our dedicated page for Lifeward news (Ticker: LFWD), a resource for investors and traders seeking the latest updates and insights on Lifeward stock.
Lifeward Ltd. reports developments for a medical technology company focused on physical rehabilitation and recovery. Its product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, MyoCycle FES System, and ReStore Exo-Suit, with use in clinical settings and in home or community rehabilitation.
Company news covers financial results, access initiatives for the FDA-cleared ReWalk Personal Exoskeleton, collaborations with rehabilitation providers, and regulatory or clinical disclosures tied to rehabilitation technologies. Other recurring updates address Nasdaq listing compliance, shareholder voting matters, governance changes, material agreements, acquisitions, and capital-structure actions involving ordinary shares and warrants.
Lifeward (Nasdaq: LFWD) reported second quarter 2026 revenue of $6.6 million, up 16% year over year, its strongest quarter since Q4 2024. Growth was led by a 13% increase in ReWalk Personal exoskeleton sales to $2.5 million and a 25% rise in AlterG products and services to $4.1 million. Gross margin was 41%, down from 44% a year earlier.
Total operating expenses fell 24% to $6.9 million, reducing GAAP operating loss by 37% to $4.2 million. GAAP net loss widened to $11.5 million, mainly from non-cash fair value charges, while non-GAAP net loss was $4.1 million. Cash and equivalents rose to $9.4 million from $2.2 million at year-end 2025, with pro forma cash of about $11 million including July financing. Lifeward highlighted a distribution pilot with Ottobock Care, progress toward a U.S. Phase 2 trial of ORMD-0801 oral insulin, and announced board departures and the planned September 30, 2026 exit of its CFO.
Lifeward (Nasdaq: LFWD) announced it will report its second quarter 2026 financial results on Friday, August 14, 2026. According to the company, a press release and the quarterly report will be made available and filed with the SEC before 9:30 a.m. ET. Lifeward also stated it will not hold a conference call in connection with this earnings release.
Lifeward (Nasdaq: LFWD) launched a six-month pilot program with Ottobock Care, a leading U.S. orthotics and prosthetics patient care organization, to expand access to the ReWalk® 7 Personal Exoskeleton.
The collaboration combines Lifeward’s neurorehabilitation exoskeleton technology with Ottobock Care’s network of more than 50 clinics, clinical expertise and patient support teams. The pilot aims to increase awareness of ReWalk 7 at rehabilitation hospitals and spinal cord injury centers, develop regional clinical and reimbursement expertise, and create sustainable local support for evaluation, training and follow-up, with the goal of establishing a scalable model for potential broader U.S. distribution.
Lifeward (Nasdaq: LFWD) arranged up to $11.2 million in strategic financing through senior secured convertible notes and warrants. An initial $5.6 million closed on July 6, 2026, with another $5.6 million contingent on specific commercial and share-price milestones.
This deal expands access to capital under a broader Oramed-linked framework of up to $47 million, of which $10 million was previously funded, supporting commercialization of Lifeward’s neurorehabilitation platform.
Oramed (NASDAQ: ORMP) released a shareholder letter detailing portfolio gains, Scilex loan repayments, and upcoming Russell 2000/3000 index inclusion.
Key points include Alpha Tau's value rising to about $167M, Scilex repayments totaling roughly $118M to date, and total cash and assets of about $270M as of March 31, 2026 (unaudited).
Lifeward (Nasdaq: LFWD) appointed Dr. Keith D. Rose as Chief Medical Officer, effective May 19, 2026, to lead its global medical strategy.
Dr. Rose brings 30 years of rehabilitation and neuroscience experience and will support expansion of Lifeward’s neurorehabilitation portfolio and newly acquired biomedical assets.
Lifeward (Nasdaq:LFWD) reported Q1 2026 revenue of $3.9 million, down 22% year-over-year, with gross margin of 34.2%. ReWalk personal exoskeleton sales rose 11% to $1.6 million, while AlterG revenue fell 38% to $2.1 million.
The company closed its Oratech strategic transaction, adding $6.5 million in cash and the Protein Oral Delivery platform, and received $10 million in financing. Operating cash burn fell 33% year-over-year, and unrestricted cash increased to $11.4 million. Lifeward will delay filing its Q1 2026 Form 10-Q to finalize accounting for the March 2026 transaction.
Lifeward (Nasdaq: LFWD) will report first quarter 2026 financial results before U.S. markets open on Friday, May 15, 2026. Management will host a conference call and live webcast at 8:30 a.m. EDT to discuss the results.
Investors can access the call via U.S. toll-free, international, and country-specific numbers or via webcast on the Lifeward investor relations website, where an archived replay will also be available.
Lifeward (Nasdaq: LFWD) presented decade-plus real‑world safety data for the ReWalk Personal Exoskeleton at ASIA 2026. A global 2013–2025 dataset shows a 3% lifetime lower‑extremity fracture prevalence, falling to 0.3% in 2020–2025. A Germany registry (2018–2025) reports zero fractures among 97 tracked users since 2018.
The analysis links most fracture events to earlier years (87% in 2014–2019) and highlights diverse patient profiles, device iterations, and increased training and device changes as likely contributors to improved safety.
Lifeward (Nasdaq: LFWD) closed its strategic partnership with Oramed on March 25, 2026, acquiring Oramed's clinical-stage POD™ protein oral delivery technology and positioning the company as a diversified biomedical innovator with an asserted clear path to profitability.
Lifeward gained access to up to $47 million of capital from Oramed and certain investors and accessed $10 million on March 25, 2026; the company also implemented changes to its board of directors.